1. Home
  2. TGTX vs PSLV Comparison

TGTX vs PSLV Comparison

Compare TGTX & PSLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TGTX
  • PSLV
  • Stock Information
  • Founded
  • TGTX 1993
  • PSLV N/A
  • Country
  • TGTX United States
  • PSLV
  • Employees
  • TGTX N/A
  • PSLV N/A
  • Industry
  • TGTX Biotechnology: Pharmaceutical Preparations
  • PSLV
  • Sector
  • TGTX Health Care
  • PSLV
  • Exchange
  • TGTX Nasdaq
  • PSLV NYSE
  • Market Cap
  • TGTX 5.4B
  • PSLV 5.1B
  • IPO Year
  • TGTX 1995
  • PSLV N/A
  • Fundamental
  • Price
  • TGTX $32.91
  • PSLV $10.11
  • Analyst Decision
  • TGTX Strong Buy
  • PSLV
  • Analyst Count
  • TGTX 6
  • PSLV 0
  • Target Price
  • TGTX $40.67
  • PSLV N/A
  • AVG Volume (30 Days)
  • TGTX 2.3M
  • PSLV N/A
  • Earning Date
  • TGTX 11-04-2024
  • PSLV N/A
  • Dividend Yield
  • TGTX N/A
  • PSLV N/A
  • EPS Growth
  • TGTX N/A
  • PSLV N/A
  • EPS
  • TGTX N/A
  • PSLV N/A
  • Revenue
  • TGTX $264,790,000.00
  • PSLV N/A
  • Revenue This Year
  • TGTX $43.74
  • PSLV N/A
  • Revenue Next Year
  • TGTX $64.30
  • PSLV N/A
  • P/E Ratio
  • TGTX N/A
  • PSLV N/A
  • Revenue Growth
  • TGTX 39.53
  • PSLV N/A
  • 52 Week Low
  • TGTX $12.84
  • PSLV N/A
  • 52 Week High
  • TGTX $36.84
  • PSLV N/A
  • Technical
  • Relative Strength Index (RSI)
  • TGTX 55.20
  • PSLV 40.18
  • Support Level
  • TGTX $30.41
  • PSLV $10.16
  • Resistance Level
  • TGTX $35.03
  • PSLV $10.28
  • Average True Range (ATR)
  • TGTX 1.55
  • PSLV 0.12
  • MACD
  • TGTX -0.33
  • PSLV -0.02
  • Stochastic Oscillator
  • TGTX 51.78
  • PSLV 1.44

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

About PSLV SPROTT PHYSICAL SILVER TRUST

Sprott Physical Silver Trust is a closed-end mutual fund trust, created to invest and hold substantially all of its assets in physical silver bullion. The Trust seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical silver bullion without the inconvenience that is typical of a direct investment in physical silver bullion. The Trust achieves its objective by investing mainly in long-term holdings of unencumbered, fully allocated, physical silver bullion and does not speculate with regard to short-term changes in silver prices.

Share on Social Networks: